

Economic Impact of Gene Expression Profiling in Patients in France

PLoS ONE

10, e0128880

DOI: [10.1371/journal.pone.0128880](https://doi.org/10.1371/journal.pone.0128880)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 427-435.	2.5	55
3	Enabling Equal Access to Molecular Diagnostics: What Are the Implications for Policy and Health Technology Assessment?. <i>Public Health Genomics</i> , 2016, 19, 144-152.	1.0	9
4	Implementation of Surgeon-Initiated Gene Expression Profile Testing (Oncotype DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. <i>Journal of Oncology Practice</i> , 2017, 13, e815-e820.	2.5	14
5	Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. <i>Cancer Treatment Reviews</i> , 2018, 62, 74-90.	7.7	61
6	Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. <i>Journal of Clinical Oncology</i> , 2018, 36, 1619-1627.	1.6	72
7	Spotlight on the utility of the Oncotype DX [®] breast cancer assay. <i>International Journal of Women's Health</i> , 2018, Volume 10, 89-100.	2.6	57
8	Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. <i>Oncologist</i> , 2019, 24, 595-602.	3.7	8
9	The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool. <i>Breast</i> , 2019, 44, 94-100.	2.2	1
10	Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. <i>Gaceta Sanitaria</i> , 2020, 34, 61-68.	1.5	9
11	Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions. <i>Journal of Clinical Oncology</i> , 2020, 38, 332-350.	1.6	25
12	Genomic Signatures in Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 355-365.	1.4	20
13	Breast cancer, screening and diagnostic tools: All you need to know. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103174.	4.4	55
14	Is radiomic MRI a feasible alternative to OncotypeDX [®] recurrence score testing? A systematic review and meta-analysis. <i>BJS Open</i> , 2021, 5, .	1.7	6
15	Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. <i>British Journal of Cancer</i> , 2021, 124, 1503-1512.	6.4	24
16	Clinicopathological correlates, oncological impact, and validation of Oncotype DX [®] in a European Tertiary Referral Centre. <i>Breast Journal</i> , 2021, 27, 521-528.	1.0	22
17	Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. <i>Cancers</i> , 2021, 13, 2282.	3.7	6
18	Challenges for the Optimization of Drug Therapy in the Treatment of Cancer. <i>Computational Biology</i> , 2020, , 163-198.	0.2	2
20	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-328.	2.8	35

#	ARTICLE	IF	CITATIONS
21	Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 245-254.	4.9	9
22	Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. <i>Ontario Health Technology Assessment Series</i> , 2020, 20, 1-234.	1.8	8
23	Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. <i>Human Pathology Reports</i> , 2021, 26, 300574.	0.3	5
24	Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211417.	3.2	0
25	Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges. <i>Value in Health</i> , 2023, 26, 1425-1434.	0.3	4
26	Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0